side			result set
DB=PGPB,USPT,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ			
L5	(chimeric or chimaeric)same(tnf$)same(cd40L or cd154 or cd40 adj ligand or 5c8 or gp39)	101	L5
L4	(L1 or L2 or L3) and (chimeric or chimaeric)same(tnf$)same(cd40L or cd154 or cd40 adj ligand or 5c8 or gp39)	2	L4
L3	cantwell.in.	360	L3
L2	kipps.in.	588	L2
L1	prussak.in.	30	L1

END OF SEARCH HISTORY

Refine Search

Search Results -

Term	Documents
CHIMERIC	57358
CHIMERICS	376
CHIMAERIC	1980
CHIMAERICS	4
CD40L	2481
CD40LS	4
CD154	1119
CD154S	6
CD40	6168
CD40S	0
LIGAND	136472
((CHIMERIC OR CHIMAERIC)SAME(TNF$)SAME(CD40L OR CD154 OR CD40 ADJ LIGAND OR 5C8 OR GP39)).PGPB,USPT,EPAB,JPAB,DWPI.	101

There are more results than shown above. Click here to view the entire set.

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L5

Refine Search

Recall Text Clear Interrupt

Search History

DATE: Tuesday, April 25, 2006 Printable Copy Create Case

Set Name side by	Query	Hit Count	Set Name

Generate Collection | Print

Search Results - Record(s) 1 through 2 of 2 returned.

☐ 1. 20050048476. 06 Dec 01. 03 Mar 05. Novel chimeric TNF ligands. Prussak, Charles E., et al. 435/6; 435/320.1 435/325 435/69.5 530/351 536/23.5 C12Q001/68 C07H021/04 C12P021/02 C12N005/06 C07K014/52.

☐ 2. WO2003050254A. New isolated polynucleotide sequence encoding a chimeric tumor necrosis factor (TNF)-alpha, useful for treating neoplasia, e.g. leukemia, gliomas, lymphomas or cancers of the breast, cervix, ovary, lung, bladder and prostate. CANTWELL, M J, et al. A61K031/7088 A61K039/00 A61K048/00 A61P035/00 C07H021/04 C07K014/52 C07K014/525 C07K019/00 C12N000/00 C12N005/06 C12N005/10 C12N015/09 C12N015/12 C12N015/62 C12P021/02 C12P021/04 C12Q001/68.

Generate Collection | Print

Term	Documents
CHIMERIC	57358
CHIMERICS	376
CHIMAERIC	1980
CHIMAERICS	4
CD40L	2481
CD40LS	4
CD154	1119
CD154S	6
CD40	6168
CD40S	0
LIGAND	136472
((L1 OR L2 OR L3) AND (CHIMERIC OR CHIMAERIC)SAME (TNF$)SAME(CD40L OR CD154 OR CD40 ADJ LIGAND OR 5C8 OR GP39)).PGPB,USPT,EPAB,JPAB,DWPI.	2

There are more results than shown above. Click here to view the entire set.

Prev Page Next Page Go to Doc#

First Hit

L4: Entry 1 of 2 File: PGPB Mar 3, 2005

PGPUB-DOCUMENT-NUMBER: 20050048476
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050048476 A1

TITLE: Novel chimeric TNF ligands

PUBLICATION-DATE: March 3, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Prussak, Charles E.	San Diego	CA	US
Kipps, Thomas J.	Rancho Santa Fe	CA	US
Cantwell, Mark J.	San Diego	CA	US

ASSIGNEE-INFORMATION:

NAME	CITY	STATE	COUNTRY	TYPE CODE
The Regents of the University of California				02

APPL-NO: 10/006305 [PALM]
DATE FILED: December 6, 2001

INT-CL-PUBLISHED: [07] C12 Q 1/68, C07 H 21/04, C12 P 21/02, C12 N 5/06, C07 K 14/52

US-CL-PUBLISHED: 435/006; 435/069.5, 435/320.1, 435/325, 530/351, 536/023.5
US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.5, 530/351, 536/23.5

REPRESENTATIVE-FIGURES: NONE

ABSTRACT:

The present invention is directed to an isolated polynucleotide sequence encoding a chimeric TNF.alpha., comprising a first nucleotide sequence encoding a domain or subdomain of a tumor necrosis factor ligand other than TNF.alpha., wherein the encoded domain or subdomain replaces a cleavage site of native TNF.alpha., and a second nucleotide sequence encoding a domain or subdomain of native TNF.alpha. that binds to a TNF.alpha. receptor. The encoded chimeric TNF.alpha. is significantly less susceptible to cleavage from the cellular surface and, as a result can increase the concentration of a ligand capable of binding to a TNF.alpha. receptor on the surface of a cell. The chimeric TNF.alpha. is therefore useful in methods for inducing apoptosis of a cell expressing a TNF.alpha. receptor, inducing activation of an immune system cell and treating neoplastic cells, by introducing into the cell of interest an isolated polynucleotide sequence encoding a chimeric TNF.alpha. that is expressed on the surface of the cell.

First Hit

L4: Entry 1 of 2 File: PGPB Mar 3, 2005

PGPUB-DOCUMENT-NUMBER: 20050048476
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050048476 A1

TITLE: Novel chimeric TNF ligands

PUBLICATION-DATE: March 3, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Prussak, Charles E.	San Diego	CA	US
Kipps, Thomas J.	Rancho Santa Fe	CA	US
Cantwell, Mark J.	San Diego	CA	US

ASSIGNEE-INFORMATION:

NAME	CITY	STATE	COUNTRY	TYPE CODE
The Regents of the University of California				02

APPL-NO: 10/006305 [PALM]
DATE FILED: December 6, 2001

INT-CL-PUBLISHED: [07] C12 Q 1/68, C07 H 21/04, C12 P 21/02, C12 N 5/06, C07 K 14/52

US-CL-PUBLISHED: 435/006; 435/069.5, 435/320.1, 435/325, 530/351, 536/023.5
US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.5, 530/351, 536/23.5

REPRESENTATIVE-FIGURES: NONE

ABSTRACT:

The present invention is directed to an isolated polynucleotide sequence encoding a chimeric TNF.alpha., comprising a first nucleotide sequence encoding a domain or subdomain of a tumor necrosis factor ligand other than TNF.alpha., wherein the encoded domain or subdomain replaces a cleavage site of native TNF.alpha., and a second nucleotide sequence encoding a domain or subdomain of native TNF.alpha. that binds to a TNF.alpha. receptor. The encoded chimeric TNF.alpha. is significantly less susceptible to cleavage from the cellular surface and, as a result can increase the concentration of a ligand capable of binding to a TNF.alpha. receptor on the surface of a cell. The chimeric TNF.alpha. is therefore useful in methods for inducing apoptosis of a cell expressing a TNF.alpha. receptor, inducing activation of an immune system cell and treating neoplastic cells, by introducing into the cell of interest an isolated polynucleotide sequence encoding a chimeric TNF.alpha. that is expressed on the surface of the cell.

```
Set     Items   Description
S1         23   E1-E4
S2         22   RD S1  (unique items)
S3        429   E1-E6
S4         83   S3 AND (CD40L OR CD40(W)LIGAND OR GP39 OR CD154 OR 5C8)
S5         63   RD S4  (unique items)
S6         20   S5 AND TNF?
S7         20   RD S6  (unique items)
S8          3   (CD40L OR CD40(W)LIGAND OR GP39 OR CD154 OR 5C8)(20N)(TNF?-
              )(20N)(CHIMERIC OR CHIMAERIC)
S9          3   RD S8  (unique items)
S10         0   (CD40L OR CD40(W)LIGAND OR GP39 OR CD154 OR 5C8)(20N)(TNF?-
              )(20N)(FUSION(W)PROETIN?)
S11        26   (CD40L OR CD40(W)LIGAND OR GP39 OR CD154 OR 5C8)(20N)(TNF?-
              )(20N)(FUSION(W)PROTEIN?)
S12        17   RD S11  (unique items)
?
```

```
 ds

Set      Items   Description
S1          23   E1-E4
S2          22   RD S1  (unique items)
S3         429   E1-E6
S4          83   S3 AND (CD40L OR CD40(W)LIGAND OR GP39 OR CD154 OR 5C8)
S5          63   RD S4  (unique items)
S6          20   S5 AND TNF?
S7          20   RD S6  (unique items)
S8           3   (CD40L OR CD40(W)LIGAND OR GP39 OR CD154 OR 5C8)(20N)(TNF?-
                 )(20N)(CHIMERIC OR CHIMAERIC)
S9           3   RD S8  (unique items)
S10          0   (CD40L OR CD40(W)LIGAND OR GP39 OR CD154 OR 5C8)(20N)(TNF?-
                 )(20N)(FUSION(W)PROETIN?)
S11         26   (CD40L OR CD40(W)LIGAND OR GP39 OR CD154 OR 5C8)(20N)(TNF?-
                 )(20N)(FUSION(W)PROTEIN?)
S12         17   RD S11  (unique items)
? s  (cd40L or cd40(w)ligand or gp39 or cd154 or 5c8)(20n)(tnf?) and (chimeric or
chimaeric)(10n)(ligand?r protein? conjugat?)
          6743  CD40L
         27276  CD40
        455163  LIGAND
         12843  CD40(W)LIGAND
           694  GP39
          3097  CD154
           135  5C8
        214105  TNF?
          1204  ((((CD40L OR CD40(W)LIGAND) OR GP39) OR CD154) OR
                5C8)(20N)TNF?
         97017  CHIMERIC
          3430  CHIMAERIC
             0  LIGAND?R PROTEIN? CONJUGAT?
             0  (CHIMERIC OR CHIMAERIC)(10N)LIGAND?R PROTEIN? CONJUGAT?
S13          0  (CD40L OR CD40(W)LIGAND OR GP39 OR CD154 OR
                5C8)(20N)(TNF?) AND (CHIMERIC OR CHIMAERIC)(10N)(LIGAND?R
                PROTEIN? CONJUGAT?)
? s  (cd40L or cd40(w)ligand or gp39 or cd154 or 5c8)(20n)(tnf?) and (chimeric or
chimaeric)(10n)(ligand? or protein? or conjugat?)
Processing
          6743  CD40L
         27276  CD40
        455163  LIGAND
         12843  CD40(W)LIGAND
           694  GP39
          3097  CD154
           135  5C8
        214105  TNF?
          1204  ((((CD40L OR CD40(W)LIGAND) OR GP39) OR CD154) OR
                5C8)(20N)TNF?
         97017  CHIMERIC
          3430  CHIMAERIC
        605586  LIGAND?
       7080631  PROTEIN?
        352062  CONJUGAT?
         41839  (CHIMERIC OR CHIMAERIC)(10N)((LIGAND? OR PROTEIN?) OR
                CONJUGAT?)
S14         13  (CD40L OR CD40(W)LIGAND OR GP39 OR CD154 OR
                5C8)(20N)(TNF?) AND (CHIMERIC OR CHIMAERIC)(10N)(LIGAND?
                OR PROTEIN? OR CONJUGAT?)
? rd s14
S15         12  RD S14  (unique items)
? t s15.3.akk'
>>>Warning: unmatched quote found
>>>'S15.3.AKK' not recognized as set or accession number
? t s15/3/all
```

```
Set     Items   Description
S1         23   E1-E4
S2         22   RD S1  (unique items)
S3        429   E1-E6
S4         83   S3 AND (CD40L OR CD40(W)LIGAND OR GP39 OR CD154 OR 5C8)
S5         63   RD S4  (unique items)
S6         20   S5 AND TNF?
S7         20   RD S6  (unique items)
S8          3   (CD40L OR CD40(W)LIGAND OR GP39 OR CD154 OR 5C8)(20N)(TNF?-
              )(20N)(CHIMERIC OR CHIMAERIC)
S9          3   RD S8  (unique items)
S10         0   (CD40L OR CD40(W)LIGAND OR GP39 OR CD154 OR 5C8)(20N)(TNF?-
              )(20N)(FUSION(W)PROETIN?)
S11        26   (CD40L OR CD40(W)LIGAND OR GP39 OR CD154 OR 5C8)(20N)(TNF?-
              )(20N)(FUSION(W)PROTEIN?)
S12        17   RD S11  (unique items)
? s  (cd40L or cd40(w)ligand or gp39 or cd154 or 5c8)(20n)(tnf?) and (chimeric or
chimaeric)(10n)(ligand?r protein? conjugat?)
          6743  CD40L
         27276  CD40
        455163  LIGAND
         12843  CD40(W)LIGAND
           694  GP39
          3097  CD154
           135  5C8
        214105  TNF?
          1204  ((((CD40L OR CD40(W)LIGAND) OR GP39) OR CD154) OR
                5C8)(20N)TNF?
         97017  CHIMERIC
          3430  CHIMAERIC
             0  LIGAND?R PROTEIN? CONJUGAT?
             0  (CHIMERIC OR CHIMAERIC)(10N)LIGAND?R PROTEIN? CONJUGAT?
    S13      0  (CD40L OR CD40(W)LIGAND OR GP39 OR CD154 OR
                5C8)(20N)(TNF?) AND (CHIMERIC OR CHIMAERIC)(10N)(LIGAND?R
                PROTEIN? CONJUGAT?)
? s  (cd40L or cd40(w)ligand or gp39 or cd154 or 5c8)(20n)(tnf?) and (chimeric or
chimaeric)(10n)(ligand? or protein? or conjugat?)
Processing
          6743  CD40L
         27276  CD40
        455163  LIGAND
         12843  CD40(W)LIGAND
           694  GP39
          3097  CD154
           135  5C8
        214105  TNF?
          1204  ((((CD40L OR CD40(W)LIGAND) OR GP39) OR CD154) OR
                5C8)(20N)TNF?
         97017  CHIMERIC
          3430  CHIMAERIC
        605586  LIGAND?
       7080631  PROTEIN?
        352062  CONJUGAT?
         41839  (CHIMERIC OR CHIMAERIC)(10N)((LIGAND? OR PROTEIN?) OR
                CONJUGAT?)
    S14     13  (CD40L OR CD40(W)LIGAND OR GP39 OR CD154 OR
                5C8)(20N)(TNF?) AND (CHIMERIC OR CHIMAERIC)(10N)(LIGAND?
                OR PROTEIN? OR CONJUGAT?)
? rd s14
    S15     12  RD S14  (unique items)
? t s15.3.akk'
>>>Warning: unmatched quote found
>>>'S15.3.AKK' not recognized as set or accession number
? t s15/3/all

 15/3/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2006 BIOSIS. All rts. reserv.
```

Gambel, Phillip

Subject: 10 /006,305 prussak

stic

please provide the following references to

phillip gambel
art unit 1644
272-0844

1644 mailbox 3c70

(((9

2/3/8 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 BIOSIS. All rts. reserv.

0013563975 BIOSIS NO.: 200200157486
Novel chimeric forms of human CD154 that can be expressed at high levels on the surface of CLL B cells
AUTHOR: Hoo William Soo (Reprint); Allen John R (Reprint); Cantwell Mark J (Reprint); Li Mei (Reprint); Kipps Thomas J; Prussak Charles E (Reprint
AUTHOR **ADDRESS: Tragen Pharmaceuticals, La Jolla, CA, USA**USA**
JOURNAL: Blood 98 (11 Part 2): p407b November 16, 2001 2001
MEDIUM: print
CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 2 Orlando, Florida, USA December 07-11, 2001; 20011207
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

**********8888

2/3/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 BIOSIS. All rts. reserv.

0013593405 BIOSIS NO.: 200200186916
Membrane-stabilized chimeric tumor necrosis factor for gene therapy of B cell malignancies
AUTHOR: Cantwell Mark J (Reprint); Li Mei (Reprint); Prussak Charles (Reprint); Kipps Thomas J
AUTHOR ADDRESS: Tragen Pharmaceuticals, La Jolla, CA, USA**USA
JOURNAL: **Blood 98 (11 Part 1): p423a November 16, 2001 2001**
MEDIUM: print
CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of

Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001; 20011207
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster
RECORD TYPE: Abstract
LANGUAGE: English

****

2/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 BIOSIS. All rts. reserv.

0014814489 BIOSIS NO.: 200400182175
Novel chimeric tumor necrosis factor-alpha has enhanced membrane stability and anti-tumor biologic activity.
AUTHOR: Cantwell Mark J (Reprint); Rieger Roman; Prussak Charles (Reprint); Kipps Thomas J
AUTHOR ADDRESS: Tragen Pharmaceuticals, San Diego, CA, USA**USA
JOURNAL: **Blood 102 (11): p500b November 16, 2003 2003**
MEDIUM: print
CONFERENCE/MEETING: 45th Annual Meeting of the American Society of Hematology San Diego, CA, USA December 06-09, 2003; 20031206
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

****

7/3/11 (Item 11 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 BIOSIS. All rts. reserv.

0013557943 BIOSIS NO.: 200200151454
Biochemical studies on the TNF family members CD154, FasL, and LIGHT using the Semliki Forest virus vector system
AUTHOR: Gutjahr Thorsten S (Reprint); Aviguetero Margaux A (Reprint); Kipps Thomas J (Reprint
AUTHOR ADDRESS: Department of Medicine, Division of Hematology/Oncology, University of California, San Diego, La Jolla, CA, USA**USA
JOURNAL: **Blood 98 (11 Part 2): p35b November 16, 2001 2001**
MEDIUM: print
CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 2 Orlando, Florida, USA December 07-11, 2001; 20011207
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract

**********8

7/7/12 (Item 12 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 BIOSIS. All rts. reserv.

0013117290 BIOSIS NO.: 200100289129
TRAF-family protein expression in normal tissues and lymphoid malignancies

AUTHOR: Zapata Juan M (Reprint); Krajewska Maryla (Reprint); Krajewski Stanislaw (Reprint); Kitada Shinichi (Reprint); Welsh Kate (Reprint); Monks Anne; McCloskey Natalie; Gordon John; Kipps Thomas; Gascoyne Randy D; Shabaik Ahmed; Reed John C (Reprint
AUTHOR ADDRESS: The Burnham Institute, La Jolla, CA, USA**USA

JOURNAL: **Blood 96 (11 Part 2): p143b November 16, 2000 2000**

MEDIUM: print
CONFERENCE/MEETING: 42nd Annual Meeting of the American Society of Hematology San Francisco, California, USA December 01-05, 2000; 20001201
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: The TRAFs constitute a family of signal transducing adapter proteins which associate with cytokine receptors, particularly the Tumor Necrosis Factor Receptor (TNFR)-family. Humans and mice contain six TRAF genes, but little information is available concerning which cell-types express these signal-transducing molecules in normal or neoplastic tissues. The in vivo locations of TRAF1, TRAF2, TRAF5, and TRAF6 were determined in human and mouse tissues by immunohistochemical methods. Striking diversity was observed in the patterns of immunostaining obtained for each of these TRAF-family proteins, suggesting that they are independently regulated and implying unique cell type-specific roles for certain TRAF-family proteins in cytokine signal transduction. Dynamic regulation of TRAFs was observed in cultured peripheral blood lymphocytes, where anti-CD3 antibodies, mitogenic lectins, and interleukins induced marked increases in the steady-state levels of TRAF1, TRAF2, TRAF5 and TRAF6. TRAF1 was also highly inducible by CD40-Ligand in cultured germinal center B-cells, whereas TRAF2, TRAF3, TRAF5, and TRAF6 were relatively unchanged. Analysis of 83 established human tumor cell lines by semi-quantitative immunoblotting methods revealed a tendency of certain types of malignant cell lines to express particular TRAFs but not others. Expression of TRAF1, for example, was highly restricted, with B-cell lymphomas most consistently expressing this TRAF-family member. Consistent with results from tumor cell lines, immunohistochemical analysis of 232 non-Hodgkin lymphoma (NHLs) revealed over-expression of TRAF1 in 112 cases (48%). TRAF1 protein levels were also elevated in circulating B-cell chronic lymphocytic leukemia (B-CLL) specimens (n=49), compared to normal peripheral blood B-cells, as determined by immunoblotting. Taken together, these findings contribute to an improved understanding of the tissue-specific roles of TRAFs in normal tissues and provide evidence of altered TRAF1 expression in lymphoid malignancies.

****

12/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 BIOSIS. All rts. reserv.

0012867962 BIOSIS NO.: 200100039801
CD40L (CD154) fusion protein with pulmonary surfactant protein D as a prototype for soluble multimeric TNF superfamily ligand molecules
AUTHOR: Kornbluth R S (Reprint); Kee K (Reprint); Truong N H (Reprint)
AUTHOR ADDRESS: University of California San Diego and VA San Diego Healthcare System, La Jolla, CA, USA**USA

JOURNAL: **FASEB Journal 14 (6): pA1162 April 20, 2000 2000**

MEDIUM: print
CONFERENCE/MEETING: Joint Annual Meeting of the American Association of Immunologists and the Clinical Immunology Society Seattle, Washington, USA

May 12-16, 2000; 20000512
ISSN: 0892-6638
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Citation
LANGUAGE: English